A Pécsi Orvostudományi Egyetem 1951-től 1999 utolsó napjáig önállóan működő orvosegyetem volt Pécsen. Az egyetem 2000. január 1-jével integrálódott a Pécsi Tudományegyetembe, annak Általános Orvostudományi Karaként.

During the past decade, Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 15 clinical trials were completed, i.e. on average, 57.7% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 9 clinical trials were completed. i.e. 128.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar" #1 sponsor was "Boston Scientific Corporation" with 5 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "University of Pecs" with 4 trials sponsored, "Pfizer" with 3 trials sponsored and "Celgene" with 3 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar" #1 collaborator was "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Cardialysis BV" with 1 trials as a collaborator, "European Association for Palliative Care" with 1 trials as a collaborator, "European Union" with 1 trials as a collaborator and "Icahn School of Medicine at Mount Sinai" with 1 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar" are "Acromegaly" (2 trials), "Arm Injury" (2 trials), "Cardiovascular Disease" (2 trials), "Chronic Rhinosinusitis" (2 trials) and "Hypoparathyroidism" (2 trials). Many other conditions were trialed in "Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar" in a lesser frequency.

Most popular intervention types in "Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar" are "Drug" (31 trials), "Procedure" (6 trials), "Device" (4 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Deep Brain Stimulation (DBS)" (2 trials), "Lenalidomide" (2 trials), "NPSP558" (2 trials) and "Omalizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar" are 43 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar". undefined are not yet recruiting, 8 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 25 completed trials in Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".